Lilly, Boehringer and Oxford End Large Phase 3 Jardiance Chronic Kidney Disease Trial Early Due to Positive Results

March 17, 2022

Eli Lilly, Boehringer Ingelheim and Oxford University are ending their phase 3 trial of Jardiance (empagliflozin) for chronic kidney disease sooner than expected because of positive efficacy seen in an interim analysis.

With more than 6,600 patients, the study was the largest dedicated SGLT2-inhibitor trial in chronic kidney disease to date. SGLT2 inhibitors prevent the kidneys from reabsorbing glucose back into the blood. Detailed results from the late-stage trial are expected to be presented later this year.

Jardiance is FDA-approved for lowering blood sugar in type 2 diabetes patients. Last month, the agency also approved it for reducing the risk of cardiovascular death and hospitalization for heart failure in adults.

View today's stories